PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-1.07%
Cash & equivalents declining -1.07% while Healthcare shows 0.00% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-1.07%
Below half the Healthcare median of 0.00% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.07%
Below half the Healthcare median of 0.00%. Jim Chanos would question if the company faces working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.07%
Below half the Healthcare median of 0.00%. Jim Chanos might see potential stagnation or distress vs. peers.
29.45%
Payables growth above 1.5x Healthcare median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.08%
Above 1.5x Healthcare median of 0.00%. Jim Chanos suspects potential working capital strain.
6.41%
Above 1.5x Healthcare median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.41%
Above 1.5x Healthcare median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
11.06%
Above 1.5x Healthcare median of 0.00%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
-3.15%
Below half Healthcare median of 0.00%. Jim Chanos suspects poor profitability or large dividend drains.
No Data
No Data available this quarter, please select a different quarter.
382.94%
Above 1.5x Healthcare median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
-11.47%
Below half Healthcare median of 0.00%. Jim Chanos suspects slower net worth growth or losses vs. peers.
-1.07%
Below half Healthcare median of 0.00%. Jim Chanos suspects a major slowdown or distress.
No Data
No Data available this quarter, please select a different quarter.
6.41%
Above 1.5x Healthcare median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
6.78%
Above 1.5x Healthcare median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.